Cortigent, Inc. (CRGT): Market Cap to Revenue Ratio

Cortigent, Inc. revenue relies on targeted patent alliances with clinics and the testing phase of neuroimplants. The P/S ratio timeline visualizes this trend, while captures the current state of the parameter. The brand's high status in neurostimulation guarantees physician trust, while streamlined medical logistics ensure the uninterrupted delivery of equipment to therapy centers.

The P/S ratio reflects the market value of the business relative to its annual revenue, allowing for an assessment of the premium paid for every dollar of sales. For Cortigent, Inc. (CRGT), whose revenues depend on the sale of high-cost neural interfaces to clinics and insurers, the P/S multiple chart helps determine how optimistically investors value future demand for stimulation systems compared to current sales volumes.